JAB-BX600​ / Jacobio Pharma - LARVOL DELTA

JAB-BX600 (First-in-class EGFR-KRAS G12Di ADC) (PRNewswire) - "IND submission planned for the second half of 2026."

IND • Solid Tumor

Jacobio Pharma Announces 2024 Annual Results (PRNewswire) - "JAB-BX600: The clinical candidate is expected to be nominated in the second half of 2025."

Pipeline update • Oncology